DAWN

Day One Biopharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 3/10
  • Momentum↑ 8/10
Day One Biopharmaceuticals sales and earnings growth
DAWN Growth
Neutral
  • Revenue Y/Y↑ 31.11%
  • EPS Y/Y↓ -47.57%
  • FCF Y/Y↓ -782.93%
Day One Biopharmaceuticals gross and profit margin trends
DAWN Profitability
Neutral
  • Gross margin ↑ 89.40%
  • EPS margin↓ -113.50%
  • ROIC↓ -35.90%
Day One Biopharmaceuticals net debt vs free cash flow
DAWN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Day One Biopharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗